Edwards Lifesciences Corporation
EW | NYSE
$92.01
-$2.43 (-2.57%)
At close: Oct 30, 2026, 4:00 PM ET
$92.01
$0.00 (0.00%)
Pre-market:
Nov 2, 2026, 8:23 AM ET
Company Profile
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Key Executives
| Name | Position |
|---|---|
| Bernard J. Zovighian | Chief Executive Officer & Director |
| Theodora Mistras | Corporate Vice President & Chief Financial Officer |
| Andrew Dahl | Principal Accounting Officer, Senior Vice President & Corporate Controller |
| Annette Maria Bruls | Corporate Vice President of EMEA, Canada, & Latin America |
| Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies |
| Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development |
| Joseph Nuzzolese | Corporate Vice President of Global Operations & Quality |
| Mark D. Peterson | Corporate Vice President & General Counsel |
| Snehashish Sarkar | Senior VP and Chief Information & Digital Officer |
| Todd Brinton FACC | Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer |
Edwards Lifesciences Corporation
| Country | United States |
| IPO Date | Mar 27, 2000 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 16,000 |
| CEO | Bernard J. Zovighian |
Contact Details
One Edwards Way Irvine,
California 92614 United States
Stock Details
| Ticker Symbol | EW |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001099800 |
| CUSIP Number | 28176E108 |
| ISIN Number | US28176E1082 |
| SIC Code | 3842 |
Recent News
- 3 days ago / zacks.comEdwards' Q3 Earnings on the Horizon: What's in the Cards?
- 3 days ago / zacks.comCurious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
- 4 days ago / seekingalpha.comEdwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives
- 11 days ago / zacks.comIs This the Right Time to Hold EW Stock in Your Portfolio?
- 26 days ago / businesswire.comEdwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- 28 days ago / businesswire.comEdwards Lifesciences to Host Investor Event in Conjunction With TCT
- 1 month ago / businesswire.comEdwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- 1 month ago / gurufocus.comIs EW Overvalued? DCF Says Worth $40
- 2 months ago / marketbeat.comEdwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
- 2 months ago / seekingalpha.comEdwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Add to Watchlist
Select watchlists to add or remove EW